MARKET

PRPH

PRPH

Prophase Labs Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.57
-0.10
-1.30%
Opening 09:30 05/19 EDT
OPEN
7.57
PREV CLOSE
7.67
HIGH
7.57
LOW
7.57
VOLUME
331
TURNOVER
2.51K
52 WEEK HIGH
8.58
52 WEEK LOW
4.238
MARKET CAP
117.23M
P/E (TTM)
93.34
1D
5D
1M
3M
1Y
5Y
ProPhase Labs to Present at the H.C. Wainwright 2022 Global Investment Conference
May 23-26, 2022 (HYBRID CONFERENCE) Garden City, NY, May 18, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present at the H.C. Wainwright 2...
GlobeNewswire · 1d ago
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global ...
ACCESSWIRE · 3d ago
--HC Wainwright Adjusts ProPhase Labs Price Target to $14 From $16, Maintains Buy Rating
MT Newswires · 3d ago
ProPhase Labs, Inc. (PRPH) Tops Q1 Earnings and Revenue Estimates
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 74.36% and 95.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
Recap: ProPhase Labs Q1 Earnings
  ProPhase Labs (NASDAQ:PRPH) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 6d ago
ProPhase Labs GAAP EPS of $0.81 beats by $0.34, revenue of $47.5M beats by $15.45M
ProPhase Labs press release (NASDAQ:PRPH): Q1 GAAP EPS of $0.81 beats by $0.34. Revenue of $47.5M (+210.5% Y/Y) beats by $15.45M. “We expect Q2 2022 to continue to produce strong
Seekingalpha · 6d ago
ProPhase Labs Q1 EPS $0.68 Beats $0.38 Estimate, Sales $47.50M Beat $24.31M Estimate
ProPhase Labs (NASDAQ:PRPH) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.38 by 78.95 percent. This is a 151.85 percent increase over earnings of $0.27 per share from the
Benzinga · 6d ago
BRIEF-ProPhase Labs Reports Q1 EPS $0.81
reuters.com · 6d ago
More
No Data
Learn about the latest financial forecast of PRPH. Analyze the recent business situations of Prophase Labs Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRPH stock price target is 10.33 with a high estimate of 14.00 and a low estimate of 5.00.
High14.00
Average10.33
Low5.00
Current 7.80
EPS
Actual
Estimate
0.000.270.530.80
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 30
Institutional Holdings: 1.55M
% Owned: 9.99%
Shares Outstanding: 15.49M
TypeInstitutionsShares
Increased
5
72.24K
New
10
143.31K
Decreased
4
15.10K
Sold Out
6
337.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Food Processing
-2.12%
Food & Tobacco
-2.22%
Key Executives
Chairman/Chief Executive Officer/Director
Ted Karkus
Chief Financial Officer
Monica Brady
Chief Operating Officer/Executive Vice President
Jason Karkus
Chief Operating Officer/Executive Vice President
Alice Lioi
Chief Investment Officer
Sergio Miralles
Other
Sam Beeler
Independent Director
Jason Barr
Independent Director
Louis Gleckel
Independent Director
Warren Hirsch
No Data
No Data
About PRPH
ProPhase Labs, Inc. is a medical science and technology company. The Company operates through two segments: consumer products and diagnostic services. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third party payers and government organizations. The Company is also engaged in development and distribution of a product line of OTC dietary supplements under the brand name of TK Supplements. The TK Supplements product line offers two men’s health products, including Legendz XL for sexual health and Triple Edge XL, an energy booster plus testosterone support.

Webull offers kinds of ProPhase Labs Inc stock information, including NASDAQ:PRPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPH stock methods without spending real money on the virtual paper trading platform.